Alk-Abello A/S logo

Alk-Abello A/S - Class B

LTS:0OIR (Denmark)   Class B
kr 149.45 (0%) Jun 20
58.28
P/B:
6.88
Market Cap:
kr 32.25B ($ 4.62B)
Enterprise V:
kr 32.48B ($ 4.65B)
Volume:
2.50K
Avg Vol (2M):
28.19K
Trade In:
Volume:
2.50K
Avg Vol (2M):
28.19K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Alk-Abello A/S ( ) from 2007 to Jun 21 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Alk-Abello A/S stock (LTS:0OIR) PE ratio as of Jun 21 2024 is 58.28. More Details

Alk-Abello A/S (LTS:0OIR) PE Ratio (TTM) Chart

To

Alk-Abello A/S (LTS:0OIR) PE Ratio (TTM) Historical Data

Total 1287
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Alk-Abello A/S PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-21 59.8 2024-04-17 59.8
2024-06-20 59.8 2024-04-16 59.8
2024-06-19 59.8 2024-04-15 59.8
2024-06-18 59.8 2024-04-12 59.8
2024-06-17 59.8 2024-04-11 59.8
2024-06-14 59.8 2024-04-10 59.8
2024-06-13 59.8 2024-04-09 59.8
2024-06-12 59.8 2024-04-08 59.8
2024-06-11 59.8 2024-04-05 59.8
2024-06-10 59.8 2024-04-04 59.8
2024-06-07 59.8 2024-04-03 59.8
2024-06-06 59.8 2024-04-02 59.8
2024-06-05 59.8 2024-03-29 59.8
2024-06-04 59.8 2024-03-28 59.8
2024-06-03 59.8 2024-03-27 71.2
2024-05-31 59.8 2024-03-26 71.2
2024-05-30 59.8 2024-03-25 71.2
2024-05-29 59.8 2024-03-22 71.2
2024-05-28 59.8 2024-03-21 71.2
2024-05-24 59.8 2024-03-20 71.2
2024-05-23 59.8 2024-03-19 71.2
2024-05-22 59.8 2024-03-18 71.2
2024-05-21 59.8 2024-03-15 71.2
2024-05-20 59.8 2024-03-14 71.2
2024-05-17 59.8 2024-03-13 71.2
2024-05-16 59.8 2024-03-12 71.2
2024-05-15 59.8 2024-03-11 71.2
2024-05-14 59.8 2024-03-08 71.2
2024-05-13 59.8 2024-03-07 71.2
2024-05-10 59.8 2024-03-06 71.2
2024-05-09 59.8 2024-03-05 71.2
2024-05-08 59.8 2024-03-04 71.2
2024-05-07 59.8 2024-03-01 71.2
2024-05-03 59.8 2024-02-29 71.2
2024-05-02 59.8 2024-02-28 71.2
2024-05-01 59.8 2024-02-27 71.2
2024-04-30 59.8 2024-02-26 71.2
2024-04-29 59.8 2024-02-23 71.2
2024-04-26 59.8 2024-02-22 71.2
2024-04-25 59.8 2024-02-21 71.2
2024-04-24 59.8 2024-02-20 71.2
2024-04-23 59.8 2024-02-19 71.2
2024-04-22 59.8 2024-02-16 71.2
2024-04-19 59.8 2024-02-15 71.2
2024-04-18 59.8 2024-02-14 71.2

Alk-Abello A/S (LTS:0OIR) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Alk-Abello A/S logo
Alk-Abello A/S
NAICS : 325412 SIC : 2834
ISIN : DK0061802139

Share Class Description:

LTS:0OIR: Class B
Description
Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.